Mylan | PCDS Scotland | Diabetes on the Net

Diabetes on the Net is intended for healthcare professionals

Company Profile

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what’s right, not what’s easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 7,500 marketed products around the world, including antiretroviral therapies on which more than 40% of people being treated for HIV/AIDS globally depend. 

We market our products in more than 165 countries and territories. We are one of the world’s largest producers of active pharmaceutical ingredients. Every member of our more than 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time.

In the UK, where some of medicines have been helping patients for more than 50 years, we have a portfolio of over 500 products that include branded, generic, over the counter, antiretroviral and biosimilar medicines. Learn more at www.mylan.co.uk.

Resources

Play Video

PEI in diabetes: Diagnosis and management in the clinic

Su Down, Nurse Consultant Diabetes,Somerset Foundation Trust

This on-demand webinar was sponsored and reviewed by Mylan.

Module

Diabetes and the gastrointestinal tract module

Production of this module has been sponsored by Mylan. Mylan have had no editorial input into the module, and full editorial control remains the sole responsibility of the Primary Care Diabetes Society. Mylan have reviewed the module for factual accuracy

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should be reported to Mylan, Building 4, Trident Place, Hatfield Business Park, Mosquito Way, Hatfield, Hertfordshire, AL10 9UL, on phone no. 0800 121 8267, Email: ukpharmacovigilance@mylan.com or +44 (0) 800 1218267

NON-2020-1863

October 2020

Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective

XX September 2020

Complete the registration form

XX Month 2020

Complete the registration form

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

* Mandatory Field
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.